Emergency cardiac surgery in patients with acute coronary syndromes: A review of the evidence and perioperative implications of medical and mechanical therapeutics

Anesthesia and Analgesia

Volumn 112, Issue 4, 2011, Pages 777-799

  Brown, Charles ^a   Joshi, Brijen ^a   Faraday, Nauder ^a   Shah, Ashish ^a   Yuh, David ^a   Rade, Jeffrey J ^a   Hogue, Charles W ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; DESMOPRESSIN; ENOXAPARIN; EPTIFIBATIDE; FONDAPARINUX; HEPARIN; HIRULOG; PLACEBO; PRASUGREL; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RETEPLASE; THROMBIN; TICAGRELOR; TICLOPIDINE; TIROFIBAN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANGIOPLASTY; ANTICOAGULANT THERAPY; AORTA BALLOON; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CARDIOGENIC SHOCK; CARDIOVASCULAR RISK; CORONARY ARTERY BYPASS GRAFT; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; ELECTROCARDIOGRAPHY; EXTRACORPOREAL OXYGENATION; GASTROINTESTINAL HEMORRHAGE; HEART ARREST; HEART ASSIST DEVICE; HEART CATHETERIZATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; LONG TERM CARE; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OVERALL SURVIVAL; PARTIAL THROMBOPLASTIN TIME; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; RESUSCITATION; SIDE EFFECT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; UNSTABLE ANGINA PECTORIS; URIC ACID BLOOD LEVEL; VENOUS THROMBOEMBOLISM;

EID: 79953206226     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e31820e7e4f     Document Type: Review

References (132)

1. Mehta SR, Cannon CP, Fox KA, Wallentin L, Boden WE, Spacek R, Widimsky P, McCullough PA, Hunt D, Braunwald E, Yusuf S. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 2005;293:2908-17 (Pubitemid 41029145)
2. American Heart Association. Heart disease and stroke statistics: 2009 update. Dallas: American Heart Association, 2009
3. Yang EH, Gumina RJ, Lennon RJ, Holmes DR Jr, Rihal CS, Singh M. Emergency coronary artery bypass surgery for percutaneous coronary interventions: changes in the incidence, clinical characteristics, and indications from 1979 to 2003. J Am Coll Cardiol 2005;46:2004-9 (Pubitemid 41713582)
4. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-22
5. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85
6. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000;355:1936-42 (Pubitemid 30326097)
7. Bonaca MP, Steg PG, Feldman LJ, Canales JF, Ferguson JJ, Wallentin L, Califf RM, Harrington RA, Giugliano RP. Antithrombotics in acute coronary syndromes. J Am Coll Cardiol 2009;54:969-84
8. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparinantithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors J Clin Invest 1990;86:385-91 (Pubitemid 20271869)
9. Weitz JI. Biological rationale for the therapeutic role of specific antithrombins. Coron Artery Dis 1996;7:409-19 (Pubitemid 26330644)
10. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE II, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non Stelevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007;116:e148- 304
11. Aranki SF, Body SC. Antiplatelet agents used for early intervention in acute coronary syndrome: myocardial salvage versus bleeding complications. J Thorac Cardiovasc Surg 2009;138:807-10
12. Kushner FG, Hand M, Smith SC Jr, King SB III, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE Jr, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO. 2009 Focused Updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 Focused Update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 Guideline and 2007 Focused Update)-a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009;120:2271-306
13. Dacey LJ, Munoz JJ, Baribeau YR, Johnson ER, Lahey SJ, Leavitt BJ, Quinn RD, Nugent WC, Birkmeyer JD, O'Connor GT. Reexploration for hemorrhage following coronary artery bypass grafting: incidence and risk factors. Northern New England Cardiovascular Disease Study Group. Arch Surg 1998;133:442-7 (Pubitemid 28193531)
14. Goodnough LT, Shander A, Brecher ME. Transfusion medicine: looking to the future. Lancet 2003;361:161-9 (Pubitemid 36092025)
15. McDonald SB, Renna M, Spitznagel EL, Avidan M, Hogue CW Jr, Moon MR, Barzilai B, Saleem R, McDonald JM, Despotis GJ. Preoperative use of enoxaparin increases the risk of postoperative bleeding and re-exploration in cardiac surgery patients. J Cardiothorac Vasc Anesth 2005;19:4-10 (Pubitemid 40259702)
16. Rao AK, Pratt C, Berke A, Jaffe A. Thrombolysis in Myocardial Infarction (TIMI) Trial. Phase I. Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11 (Pubitemid 18029027)
17. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82
18. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006;114:774-82 (Pubitemid 44268228)
19. Van de Werf F. Balancing benefit and bleeding risk of antithrombotic agents in the individual patient with an acute coronary syndrome. Circulation 2010;121:5-7
20. Pocock SJ, Mehran R, Clayton TC, Nikolsky E, Parise H, Fahy M, Lansky AJ, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Stone GW. Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy Trial. Circulation 2010;121:43-51
21. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502 (Pubitemid 32758501)
22. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-21
23. Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, Yusuf S. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable Angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004;110:1202-8 (Pubitemid 39202333)
24. Sabatine M, Cannon C, Gibson C, Lopez-Sendon J, Montalescot G, Theroux P, Claeys M, Cools F, Hill K, Skene A, McCabe C, Braunwald E. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with Stsegment elevation. N Engl J Med 2005;352:1179-89 (Pubitemid 40397259)
25. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045-57
26. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15 (Pubitemid 350106708)
27. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-62
28. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45: 246-51 (Pubitemid 40094733)
29. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302:849-57
30. Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 2006;4:2508-9 (Pubitemid 44575451)
31. Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, Jakubowski JA, Naganuma H, Winters KJ. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007;153:66.e9-16
32. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006;27:1166-73
33. Bowry AD, Brookhart MA, Choudhry NK. Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events. Am J Cardiol 2008;101:960-6
34. Rade JJ, Hogue CW Jr. Noncardiac surgery for patients with coronary artery stents: timing is everything. Anesthesiology 2008;109:573-8
35. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, Kramer JM, Harrington RA, Matchar DB, Kandzari DE, Peterson ED, Schulman KA, Califf RM. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297:159-68 (Pubitemid 46089732)
36. Ascione R, Ghosh A, Rogers CA, Cohen A, Monk C, Angelini GD. In-hospital patients exposed to clopidogrel before coronary artery bypass graft surgery: a word of caution. Ann Thorac Surg 2005;79:1210-6 (Pubitemid 40431840)
37. Chu MW, Wilson SR, Novick RJ, Stitt LW, Quantz MA. Does clopidogrel increase blood loss following coronary artery bypass surgery? Ann Thorac Surg 2004;78:1536-41 (Pubitemid 39423508)
38. Hongo RH, Ley J, Dick SE, Yee RR. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 2002;40:231-7 (Pubitemid 34756281)
39. Kapetanakis EI, Medlam DA, Boyce SW, Haile E, Hill PC, Dullum MK, Bafi AS, Petro KR, Corso PJ. Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist's panacea or the surgeon's headache? Eur Heart J 2005;26:576-83 (Pubitemid 40461099)
40. Blasco-Colmenares E, Perl TM, Guallar E, Baumgartner WA, Conte JV, Alejo D, Pastor-Barriuso R, Sharrett AR, Faraday N. Aspirin plus clopidogrel and risk of infection after coronary artery bypass surgery. Arch Intern Med 2009;169:788-96
41. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/ OFFSET study. Circulation 2009;120:2577-85
42. McLean DS, Sabatine MS, Guo W, McCabe CH, annon CP. Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITYTIMI 28 J Thromb Thrombolysis 2007;24:85-91
43. Goto K, Lansky AJ, Fahy M, Cristea E, Feit F, Ohman EM, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Mehran R, Stone GW. Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy. Circulation 2010; 121:853-62
44. Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L, Andersen HR, Betriu A, Savonitto S, Adamus J, Peruga JZ, Kosmider M, Katz O, Neunteufl T, Jorgova J, Dorobantu M, Grinfeld L, Armstrong P, Brodie BR, Herrmann HC, Montalescot G, Neumann FJ, Effron MB, Barnathan ES, Topol EJ; FINESSE Investigators. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008;358:2205-17 (Pubitemid 351724450)
45. Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van't Hof A, Berdan LG, Lee KL, Strony JT, Hildemann S, Veltri E, Van de Werf F, Braunwald E, Harrington RA, Califf RM, Newby LK; EARLY ACS Investigators. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 2009;360:2176-90
46. Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schuhlen H, Dirschinger J, Berger PB, Schomig A. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006;295:1531-8
47. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349:1429-35
48. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000;356: 2037-44
49. The IMPACT-II Investigators. Randomised placebocontrolled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997;349:1422-8
50. The PRISM PLUS Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97
51. The PURSUIT Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43
52. Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90:1757-64 (Pubitemid 24320922)
53. Boersma E, Harrington RA, Moliterno DJ, White H, Théroux P, Van de Werf F, de Torbal A, Armstrong PW, Wallentin LC, Wilcox RG, Simes J, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-98 (Pubitemid 34113814)
54. Tsai TT, Maddox TM, Roe MT, Dai D, Alexander KP, Ho PM, Messenger JC, Nallamothu BK, Peterson ED, Rumsfeld JS. Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. JAMA 2009; 302:2458-64
55. Lincoff AM, LeNarz LA, Despotis GJ, Smith PK, Booth JE, Raymond RE, Sapp SK, Cabot CF, Tcheng JE, Califf RM, Effron MB, Topol EJ. Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing. Ann Thorac Surg 2000;70:516-26
56. Gammie JS, Zenati M, Kormos RL, Hattler BG, Wei LM, Pellegrini RV, Griffith BP, Dyke CM. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations. Ann Thorac Surg 1998;65:465-9 (Pubitemid 28083346)
57. Bizzarri F, Scolletta S, Tucci E, Lucidi M, Davoli G, Toscano T, Neri E, Muzzi L, Frati G. Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001;122:1181-5
58. Dyke CM, Bhatia D, Lorenz TJ, Marso SP, Tardiff BE, Hogeboom C, Harrington RA. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy. Ann Thorac Surg 2000;70:866-71
59. Fox KA, Antman EM, Montalescot G, Agewall S, SomaRaju B, Verheugt FW, Lopez-Sendon J, Hod H, Murphy SA, Braunwald E. The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 2007;49:2249-55 (Pubitemid 46863477)
60. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:188S-203S (Pubitemid 39297954)
61. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997;337:447-52 (Pubitemid 27333045)
62. Cohen M, Théroux P, Borzak S, Frey MJ, White HD, Van Mieghem W, Senatore F, Lis J, Mukherjee R, Harris K, Bigonzi F. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. Am Heart J 2002;144:470-7
63. Goodman SG, Fitchett D, Armstrong PW, Tan M, Langer A. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003;107:238-44 (Pubitemid 36135218)
64. Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, Budaj A, López-Sendón JL, Guneri S, Jiang F, White HD, Fox KA, Braunwald E; ExTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006;354:1477-88
65. Bhatt DL, Lee BI, Casterella PJ, Pulsipher M, Rogers M, Cohen M, Corrigan VE, Ryan TJ Jr, Breall JA, Moses JW, Eaton GM, Sklar MA, Lincoff AM; Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. J Am Coll Cardiol 2003;41:20-5 (Pubitemid 36044398)
66. Kereiakes DJ, Grines C, Fry E, Esente P, Hoppensteadt D, Midei M, Barr L, Matthai W, Todd M, Broderick T, Rubinstein R, Fareed J, Santoian E, Neiderman A, Brodie B, Zidar J, Ferguson JJ, Cohen M. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol 2001;13:272-8 (Pubitemid 33759464)
67. Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, Bode C, Chiariello M, King SB III, Arrington RA, Desmet WJ, Macaya C, Steinhubl SR. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006;355:1006-17 (Pubitemid 44343544)
68. Petersen JL, Mahaffey KW, Hasselblad V, Antman EM, Cohen M, Goodman SG, Langer A, Blazing MA, Le-Moigne-Amrani A, de Lemos JA, Nessel CC, Harrington RA, Ferguson JJ, Braunwald E, Califf RM. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. JAMA 2004;292:89-96 (Pubitemid 38923799)
69. Blazing MA, de Lemos JA, White HD, Fox KA, Verheugt FW, Ardissino D, DiBattiste PM, Palmisano J, Bilheimer DW, Snapinn SM, Ramsey KE, Gardner LH, Hasselblad V, Pfeffer MA, Lewis EF, Braunwald E, Califf RM; 'A to Z' Investigators. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 2004;292:55-64 (Pubitemid 38923794)
70. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H; SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in highrisk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292:45-54 (Pubitemid 38923793)
71. Gibson CM, Murphy SA, Montalescot G, Morrow DA, Ardissino D, Cohen M, Gulba DC, Kracoff OH, Lewis BS, Roguin N, Antman EM, Braunwald E; ExTRACT-TIMI 25 Investigators. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACTTIMI 25 trial. J Am Coll Cardiol 2007;49:2238-46 (Pubitemid 46856824)
72. Chew DP, Mahaffey KW, White HD, Huang Z, Hoekstra JW, Ferguson JJ, Califf RM, Aylward PE. Coronary artery bypass surgery in patients with acute coronary syndromes is difficult to predict. Am Heart J 2008;155:841-7
73. The Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet 2002;359:294-302
74. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-63 (Pubitemid 37430344)
75. Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004;292:696-703 (Pubitemid 39062523)
76. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203-16 (Pubitemid 44791162)
77. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R; HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-30 (Pubitemid 351724451)
78. Bittle J, Strony J, Brinker J, Ahmed W, Meckel C, Chairman B, Maraganore J, Deutsch E, Adelman B. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 1995;333: 764-9
79. Kastrati A, Neumann FJ, Mehilli J, Byrne R, Iijima R, Bü ttner H, Khattab A, Schulz S, Blankenship J, Pache J, Minners J, Seyfarth M, Graf I, Skelding K, Dirschinger J, Richardt G, Berger P, Schömig A. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008;359:688-96
80. Doll JA, Nikolsky E, Stone GW, Mehran R, Lincoff AM, Caixeta A, McLaurin B, Cristea E, Fahy M, Kesanakurthy V, Lansky AJ. Outcomes of patients with coronary artery perforation complicating percutaneous coronary intervention and correlations with the type of adjunctive antithrombotic therapy: pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials. J Interv Cardiol 2009;22:453-9
81. Smedira NG, Dyke CM, Koster A, Jurmann M, Bhatia DS, Hu T, McCarthy HL II, Lincoff AM, Spiess BD, Aronson S. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg 2006;131:686-92
82. Koster A, Spiess B, Jurmann M, Dyke CM, Smedira NG, Aronson S, Lincoff MA. Bivalirudin provides rapid, effective, and reliable anticoagulation during off-pump coronary revascularization: results of the EVOLUTION OFF trial. Anesth Analg 2006;103:540-4 (Pubitemid 44542900)
83. Koster A, Dyke CM, Aldea G, Smedira NG, McCarthy HL II, Aronson S, Hetzer R, Avery E, Spiess B, Lincoff AM. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg 2007;83:572-7 (Pubitemid 46156924)
84. Dyke CM, Aldea G, Koster A, Smedira N, Avery E, Aronson S, Spiess BD, Lincoff AM. Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies. Ann Thorac Surg 2007;84:836-9 (Pubitemid 47285016)
85. Bauer KA. Fondaparinux: a new synthetic and selective inhibitor of factor Xa. Best Pract Res Clin Haematol 2004;17:89-104 (Pubitemid 38786420)
86. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox K. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006;354:1464-76
87. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox K; OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006;295:1519-30
88. Levy JH. Pharmacologic preservation of the hemostatic system during cardiac surgery. Ann Thorac Surg 2001;72:S1814-20 (Pubitemid 33049833)
89. O'Riordan JM, Margey RJ, Blake G, O'Connell PR. Antiplatelet agents in the perioperative period. Arch Surg 2009;144:69-76
90. Vilahur G, Choi BG, Zafar MU, Viles-Gonzalez JF, Vorchheimer DA, Fuster V, Badimon JJ. Normalization of platelet reactivity in clopidogrel-treated subjects. J Thromb Haemost 2007;5:82-90 (Pubitemid 44921071)
91. Tanaka KA, Key NS, Levy JH. Blood coagulation: hemostasis and thrombin regulation. Anesth Analg 2009;108:1433-46
92. U.S. Food and Drug Administration. NovoSeven. Available at: http://www.fda.gov/BiologicsBloodVaccines/BloodBlood Products/ApprovedProducts/ LicensedProductsBLAs/ FractionatedPlasmaProducts/ucm089228.htm, 2009. Accessed January 31, 2011.
93. Monroe DM, Hoffman M. What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol 2006;26:41-8 (Pubitemid 43732226)
94. Novo Nordisk, Inc. NovoSeven RT package insert, 2010
95. Gill R, Herbertson M, Vuylsteke A, Olsen PS, von Heymann C, Mythen M, Sellke F, Booth F, Schmidt TA. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation 2009;120:21-7
96. Herbertson M. Recombinant activated factor VII in cardiac surgery. Blood Coagul Fibrinolysis 2004;15:S31-2 (Pubitemid 38757074)
97. Isbister J, Phillips L, Dunkley S, Jankelowitz G, McNeil J, Cameron P. Recombinant activated factor VII in critical bleeding: experience from the Australian and New Zealand Haemostasis Register. Intern Med J 2008;38:156-65 (Pubitemid 351271402)
98. McCall P, Story DA, Karalapillai D. Audit of factor VIIa for bleeding resistant to conventional therapy following complex cardiac surgery. Can J Anaesth 2006;53:926-33 (Pubitemid 44696517)
99. von Heymann C, Redlich U, Jain U, Kastrup M, Schroeder T, Sander M, Grosse J, Ziemer S, Koscielny J, Konertz WF, Wernecke KD, Spies C. Recombinant activated factor VII for refractory bleeding after cardiac surgery: a retrospective analysis of safety and efficacy. Crit Care Med 2005;33:2241-6 (Pubitemid 41437477)
100. Karkouti K, Yau TM, Riazi S, Dattilo KM, Wasowicz M, Meineri M, McCluskey SA, Wijeysundera DN, van Rensburg A, Beattie WS. Determinants of complications with recombinant factor VIIa for refractory blood loss in cardiac surgery. Can J Anaesth 2006;53:802-9 (Pubitemid 44420066)
101. Barron HV, Every NR, Parsons LS, Angeja B, Goldberg RJ, Gore JM, Chou TM. The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the National Registry of Myocardial Infarction 2. Am Heart J 2001;141:933-9
102. Cook S, Windecker S. Percutaneous ventricular assist devices for cardiogenic shock. Curr Heart Fail Rep 2008;5:163-9
103. Sanborn TA, Sleeper LA, Bates ER, Jacobs AK, Boland J, French JK, Dens J, Dzavik V, Palmeri ST, Webb JG, Goldberger M, Hochman JS. Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 2000;36:1123-9
104. Stone GW, Marsalese D, Brodie BR, Griffin JJ, Donohue B, Costantini C, Balestrini C, Wharton T, Esente P, Spain M, Moses J, Nobuyoshi M, Ayres M, Jones D, Mason D, Grines L, O'Neill WW, Grines CL. A prospective, randomized evaluation of prophylactic intraaortic balloon counterpulsation in high risk patients with acute myocardial infarction treated with primary angioplasty. Second Primary Angioplasty in Myocardial Infarction (PAMI-II) Trial Investigators. J Am Coll Cardiol1997;29:1459-67 (Pubitemid 27272437)
105. van't Hof AW, Liem AL, de Boer MJ, Hoorntje JC, Suryapranata H, Zijlstra F. A randomized comparison of intra-aortic balloon pumping after primary coronary angioplasty in high risk patients with acute myocardial infarction. Eur
106. Hill JD, O'Brien TG, Murray JJ, Dontigny L, Bramson ML, Osborn JJ, Gerbode F. Prolonged extracorporeal oxygenation for acute post-traumatic respiratory failure (shock-lung syndrome): use of the Bramson membrane lung. N Engl J Med 1972;286:629-34
107. Zapol WM, Snider MT, Hill JD, Fallat RJ, Bartlett RH, Edmunds LH, Morris AH, Peirce EC II, Thomas AN, Proctor HJ, Drinker PA, Pratt PC, Bagniewski A, Miller RG Jr. Extracorporeal membrane oxygenation in severe acute respiratory failure: a randomized prospective study. JAMA 1979;242:2193-6 (Pubitemid 10195729)
108. Sidebotham D, McGeorge A, McGuinness S, Edwards M, Willcox T, Beca J. Extracorporeal membrane oxygenation for treating severe cardiac and respiratory disease in adults: Part 1. Overview of extracorporeal membrane oxygenation. J Cardiothorac Vasc Anesth 2009;23:886-92
109. LaFayette NG, Schewe RE, Montoya JP, Cook KE. Performance of a MedArray silicone hollow fiber oxygenator. ASAIO J 2009;55:382-7
110. Mottaghy K, Oedekoven B, Starmans H, Mü ller B, Kashefi A, Hoffmann B, Böhm S. Technical aspects of plasma leakage prevention in microporous capillary membrane oxygenators. ASAIO J 1989;38:640-3 (Pubitemid 20118331)
111. Peek GJ, Killer HM, Reeves R, Sosnowski AW, Firmin RK. Early experience with a polymethyl pentene oxygenator for adult extracorporeal life support. ASAIO J 2002;48:390-7
112. Toomasian JM, Schreiner RJ, Meyer DE, Schmidt ME, Hagan SE, Griffith GW, Bartlett RH, Cook KE. A polymethylpentene fiber gas exchanger for long-term extracorporeal life support. ASAIO J 2005;51:390-7 (Pubitemid 41076775)
113. Formica F, Avalli L, Martino A, Maggioni E, Muratore M, Ferro O, Pesenti A, Paolini G. Extracorporeal membrane oxygenation with a poly-methylpentene oxygenator (Quadrox D): the experience of a single Italian centre in adult patients with refractory cardiogenic shock. ASAIO J 2008;54:89-94
114. Cardarelli MG, Young AJ, Griffith B. Use of extracorporeal membrane oxygenation for adults in cardiac arrest (E-CPR): a meta-analysis of observational studies. ASAIO J 2009;55:581-6
115. Seyfarth M, Sibbing D, Bauer I, Frohlich G, Bott-Flugel L, Byrne R, Dirschinger J, Kastrati A, Schomig A. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol 2008;52:1584-8
116. Thiagarajan RR, Brogan TV, Scheurer MA, Laussen PC, Rycus PT, Bratton SL. Extracorporeal membrane oxygenation to support cardiopulmonary resuscitation in adults. Ann Thorac Surg 2009;87:778-85
117. Peberdy MA, Kaye W, Ornato JP, Larkin GL, Nadkarni V, Mancini ME, Berg RA, Nichol G, Lane-Trultt T. Cardiopulmonary resuscitation of adults in the hospital: a report of 14720 cardiac arrests from the National Registry of Cardiopulmonary Resuscitation. Resuscitation 2003;58:297-308 (Pubitemid 37101156)
118. Tayara W, Starling RC, Yamani MH, Wazni O, Jubran F, Smedira N. Improved survival after acute myocardial infarction complicated by cardiogenic shock with circulatory support and transplantation: comparing aggressive intervention with conservative treatment. J Heart Lung Transplant 2006;25:504-9 (Pubitemid 44308155)
119. Thiele H, Lauer B, Hambrecht R, Boudriot E, Cohen HA, Schuler G. Reversal of cardiogenic shock by percutaneous left atrial-to-femoral arterial bypass assistance. Circulation 2001;104:2917-22 (Pubitemid 33139103)
120. Burkhoff D, O'Neill W, Brunckhorst C, Letts D, Lasorda D, Cohen HA. Feasibility study of the use of the TandemHeart percutaneous ventricular assist device for treatment of cardiogenic shock. Catheter Cardiovasc Interv 2006;68:211-7 (Pubitemid 44167670)
121. Pitsis AA, Visouli AN, Burkhoff D, Dardas P, Mezilis N, Bougioukas G, Filippatos G. Feasibility study of a temporary percutaneous left ventricular assist device in cardiac surgery. Ann Thorac Surg 2007;84:1993-9 (Pubitemid 350122402)
122. Brinkman WT, Rosenthal JE, Eichhorn E, Dewey TM, Magee MJ, Savor DS, Riley AG, Prince SL, Worley CM, Herbert MA, Mack MJ. Role of a percutaneous ventricular assist device in decision making for a cardiac transplant program. Ann Thorac Surg 2009;88:1462-6
123. Burkhoff D, Cohen H, Brunckhorst C, O'Neill WW; Tandem- Heart Investigators Group. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J 2006;152:e1-8
124. Thiele H, Sick P, Boudriot E, Diederich KW, Hambrecht R, Niebauer J, Schuler G. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 2005;26:1276-83 (Pubitemid 41435457)
125. Henriques JP, Remmelink M, Baan J Jr, van der Schaaf RJ, Vis MM, Koch KT, Scholten EW, de Mol BA, Tijssen JG, Piek JJ, de Winter RJ. Safety and feasibility of elective high-risk percutaneous coronary intervention procedures with left ventricular support of the Impella Recover LP 2.5. Am J Cardiol 2006;97:990-2
126. Rossiter-Thornton M, Arun V, Forrest AP, Bayfield MS, Wilson MK. Left ventricular support with the Impella LP 5.0 for cardiogenic shock following cardiac surgery. Heart Lung Circ 2008;17:243-5
127. Garatti A, Colombo T, Russo C, Lanfranconi M, Milazzo F, Catena E, Bruschi G, Frigerio M, Vitali E. Left ventricular mechanical support with the Impella Recover left direct microaxial blood pump: a single-center experience. Artif Organs 2006;30:523-8 (Pubitemid 43961704)
128. Samoukovic G, Rosu C, Giannetti N, Cecere R. The Impella LP 5.0 as a bridge to long-term circulatory support. Interact Cardiovasc Thorac Surg 2009;8:682-3
129. Windecker S. Percutaneous left ventricular assist devices for treatment of patients with cardiogenic shock. Curr Opin Crit Care 2007;13:521-7 (Pubitemid 47357452)
130. Valgimigli M, Steendijk P, Sianos G, Onderwater E, Serruys PW. Left ventricular unloading and concomitant total cardiac output increase by the use of percutaneous Impella Recover LP 2.5 assist device during high-risk coronary intervention. Catheter Cardiovasc Interv 2005;65:263-7 (Pubitemid 40791523)
131. Pretorius M, Hughes AK, Stahlman MB, Saavedra PJ, Deegan RJ, Greelish JP, Zhao DX. Placement of the TandemHeart percutaneous left ventricular assist device. Anesth Analg 2006;103:1412-3 (Pubitemid 44949206)
132. Vlasselaers D, Desmet M, Desmet L, Meyns B, Dens J. Ventricular unloading with a miniature axial flow pump in combination with extracorporeal membrane oxygenation. Intensive Care Med 2006;32:329-33 (Pubitemid 43251160)